Drug-device combination products

Drug-Device Combination Products: Delivery Technologies and Applications

Volumn , Issue , 2009, Pages 3-28

  Wang, Y ^a   Burgess, D J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DELIVERY;

COMBINATION PRODUCTS; DRUG DELIVERY SYSTEM; DRUG-ELUTING STENTS; MEDICAL DEVICE COMPANIES; MEDICAL DEVICES; ORTHOPEDIC DEVICES; PHARMACEUTICAL INDUSTRY;

DRUG PRODUCTS;

EID: 84903347337     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9781845697488.1.3     Document Type: Chapter

References (139)

1. US Food and Drug Administration, Part 3 ± Production Jurisdiction. 21 CFR Food and Drugs, chapter I.
2. Smita Gopalaswamy V.G. Overview of combination products. Combination Products: Regulatory Challenges and Successful Product Development 2008, CRC Press. V.G. Smita Gopalaswamy (Ed.).
3. Yoshinori Onuki U.B., Papadimitrakopoulos F., Burgess D.J. A review of the biocompatibility of implantable devices: current challenges to overcome foreign body response. J Diabetes Sci Technol 2008, 2(6):1003-1015.
4. Carsenti-Dellamonica H. Infections associated with orthopedic implanted devices. Antibiotiques 2008, 10(1):3-15.
5. Mccann M.T.G., Brendan F., Gorman S.P. Staphylococcus epidermidis device-related infections: pathogenesis and clinical management. J Pharm Pharmacol 2008, 60(12):1551-1571.
6. Peng Wu D.W.G. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 2006, 27:2450-2467.
7. Indolfi C.M., Curcio A., Antonio Torella D. Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovascular Med 2003, 13(4):142-148.
8. Walter D.H., Diaz-Sandoval L., Willis S., Kirkwood L., Stratford P.W., Tietz A.B., Kirchmair R., Silver M., Curry C., Wecker A., Yoon Y.-S., Heidenreich R., Hanley A., Kearney M., Tio F.O., Kuenzler P., Isner J.M., Losordo D.W. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. American Heart Association Inc 2004, 110:36-38. (available online).
9. Imad Sheiban G.V., Bollati M., Sillano D., Lotrionte M., Biondi-Zoccai G. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®). Vase Health Risk Manag 2008, 4(1):31-38.
10. Burke S.E., Kuntz R.E., Schwartz L.B. Zotarolimus (ABT-578) eluting stents. Adv Drug Delivery Rev 2006, 58(3):437-446.
11. Swanson N., et al. Vascular endothelial growth factor (VEGF)-eluting stents: in vivo effects on thrombosis, endothelialization and intimal hyperplasia. J Invasive Cardiol 2003, 15(12):688-692.
12. Sharif F., et al. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. Mol Ther 2008, 16(10):1674-1680.
13. Duda S.H., et al. Drug-eluting stents: potential applications for peripheral arterial occlusive disease. J Vascular Interventional Radiol 2003, 14(3):291-301.
14. Berger H.L. Coating drug-eluting arterial stents using ultrasonic spray nozzles 2006.
15. Chen M.-C., et al. A novel drug-eluting stent spray-coated with multi-layers of collagen and sirolimus. J Controlled Rel 2005, 108(1):178-189.
16. Salu K.J., Bosmans J.M., Huang Y., Hendriks M., Verhoeven M., Levels A., Cooper S., De Scheerder I.K., Vrints C.J., Bult H. Effects of cytochalasin D- eluting stents on intimal hyperplasia in a porcine coronary artery model. Cardiovascular Res 2006, 69:536-544.
17. Edelman E.R., Seifert P., Groothuis A., Morss A., Bornstein B., Rogers C. Gold-coated NIR stents in porcine coronary arteries. American Heart Association, Inc. 2001, 103:429-434. (available online).
18. Landy Mark T.A., Chen M., Manus T. Method of coating medical devices. PCT Int. Appl 2009, 42.
19. Yongpeng Chen G.W., Jin X., Luo L. Coating preparation and drug delayed release of dexamethasone-eluting intravascular stents in vitro and in vivo. IFMBE Proceedings 2008.
20. Kleiner L.W., Desnoyer J.R., Maslanka B.Z., Trollsas M.O. Implantable medical devices such as stents having thin absorbable coating for controlled delivery of drugs. PCT Int. Appl. 2009, 32.
21. Rosenberg R.T., Siegel S.J., Nily D. Release of highly hydrophilic drugs from poly(e-caprolactone) matrices. J Appl Polym Sci 2008, 107(5):3149-3156.
22. Zheng H., et al. Layer-by-layer assembly of enzymes and polymerized mediator on electrode surface by electrostatic adsorption. Sci Technol Adv Mater 2004, 5(3):371-376.
23. Ali Javey S.N., Friedman R.S., Yan H., Lieber C.M. Layer-by-layer assembly of nanowires for three-dimensional, multifunctional electronics. Nano Lett 2007, 7(3):773-777.
24. Zhang Z., Cao X., Zhao X., Holt C.M., Lewis A.L., Lu J.R. Controlled delivery of anti-sense oligonucleotide from multilayered biocompatible phosphorylcholine polymer films. J Control Rel 2008, 130(1):69-76.
25. Moreno R., Fernandez C., Hernandez R., Alfonso F., Angiolillo D.J., Sabate M., Escaned J., Banuelos C., Fernandez-Ortiz A., Macaya C. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005, 45(6):954-959.
26. Windecker S., Serruys P.W., Wandel S., Buszman P., Trznadel S., Linke A., Lenk K., Ischinger T., Klauss V., Eberli F., Corti R., Wijns W., Morice M.C., Di Mario C., Davies S., Van Geuns R.J., Eerdmans P., Van Es G.A., Meier B., Jiini P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008, 372(9644):1163-1173.
27. Grizzi I., et al. Hydrolytic degradation of devices based on poly(-lactic acid) size-dependence. Biomaterials 1995, 16(4):305-311.
28. Yoo J.Y., Kim J.M., Seo K.S., Jeong Y.K., Lee H.B., Khang A.G. Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method. Bio-Medical Mater Eng 2005, 15:279-288.
29. Loo J.S.C., Ooi C.P., Boey F.Y.C. Degradation of poly(lactide-co-glycolide) (PLGA) and poly(-lactide) (PLLA) by electron beam radiation. Biomaterials 2005, 26(12):1359-1367.
30. Lichun Lu C.A.G., Mikos A.G. In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films. J Biomed Mater Res Part B: Appl Biomater 1999, 46(2):236-244.
31. Lewis A.L., Stafford P.W. Phosphorylcholine-coated stents. Journal of Long Term Effects of Medical Implants 2002, 12:231-250.
32. Roosjen A., De Vries J., Van Der Mei H.C., Norde W., Busscher H.J. Stability and effectiveness against bacterial adhesion of poly(ethylene oxide) coatings in biological fluids. J Biomed Mater Res Part B: Appl Biomater 2005, 73B(2):347-354.
33. Dong P., et al. Fabrication and biocompatibility of polyethyleneimine/heparin self-assembly coating on NiTi alloy. Thin Solid Films 2008, 516(16):5168-5171.
34. Belboul A., Al-Khaja N. Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery. Perfusion 1997, 12(6):385-391.
35. Noguchi M., Eishi K., Tada S., Yamachika S., Hazama S., Izumi K., Tanigawa K. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass. Ann Thorac Cardiovasc Surg 2003, 9(1):22-28.
36. Kong X., et al. Effect of biologically active coating on biocompatibility of Nitinol devices designed for the closure of intra-atrial communications. Biomaterials 2002, 23(8):1775-1783.
37. Marois Y., et al. An albumin-coated polyester arterial graft: in vivo assessment of biocompatibility and healing characteristics. Biomaterials 1996, 17(1):3-14.
38. Mehilli J., Kastrati A., Wessely R., Dibra A., Hausleiter J., Jaschke B., Dirschinger J., Schomig A. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006, 113:273-279.
39. Costa J.R., Alexandra A., Costa R., Feres F., Tanajura L.F., Abizaid A., Mattos L.A., Staico R., Siqueira D., Sousa A.G.M.R., Bonan R., Sousa J.E. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions: a first-in-human analysis of a third-generation drug-eluting stent system. J Am Coll Cardiol Intv 2008, 1:545-551.
40. Frenning G., Stramme M. Drug release modeled by dissolution, diffusion, and immobilization. Int J Pharmaceutics 2003, 250(1):137-145.
41. Ghanashyam Acharya K.P. Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Delivery Rev 2006, 58:387-401.
42. Shiga Y., Minami K., Segawa K., Uezono Y., Shiraishi M., Sata T., Yamamoto C., Sung-Teh K. The inhibition of aortic smooth muscle cell proliferation by the intravenous anesthetic ketamine. Anesthesia & Analgesia vol. 99, International Anesthesia Research Society 2004, 1408-1412.
43. Hedin U., Roy J., Tran P.K. Control of smooth muscle cell proliferation in vascular disease. Curr Opin Lipidol 2004, 15(5):559-565.
44. Huang M.-H., Li S., Vert M. Synthesis and degradation of PLA-PCL-PLA triblock copolymer prepared by successive polymerization of e-caprolactone and DL-lactide. Polymer 2004, 45(26):8675-8681.
45. Whelan D.M., Van Der Giessen W.J., Krabbendam S.C., Van Vliet E.A., Verdouw P.D., Serruys P.W., Van Beusekom H.M.M. Biocompatibility of phosphoryl-choline coated stents in normal porcine coronary. Heart 2000, 83:338-345.
46. Lewis A.L., Berwick J., Davies M.C., Roberts C.J., Wang J.H., Small S., Dunn A., O'Byrne V., Redman R.P., Jones S.A. Synthesis and characterisation of cationically-modified phospholipid polymers. Biomaterials 2004, 25(15):3099-3108.
47. Palmer R.R., Lewis A.L., Kirkwood L.C., Rose S.F.W., Lloyd A.W., Vick T.A., Stratford P.W. Biological evaluation and drug delivery application of cationically-modified phospholiqid polymers. Biomaterials 2003, 25(19):4785-4796.
48. Chatzinikolaou I., Raad I. Central venous catheter related infections: the role of antimicrobial catheters. Mol Cell Biol Crit Care Med 2003, 3:187-215.
49. Pittet D., Tarara D., Wenzel R.P. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994, 271:1598-1602.
50. Chatzinikolaou I., et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. AJM 2003, 115(5):352-357.
51. Warren D.K., Zack J.E., Cox M.J., Cohen M.M., Fraser V.J. An educational intervention to prevent catheter-associated bloodstream infections in a nonteaching, community medical center. Crit Care Med 2003, 31:1959-1963.
52. Elliott T.S. Can antimicrobial central venous catheters prevent associated infection?. Br J Haematol 1999, 107:235-241.
53. Mermel L.A., Stolz S.M., Maki D.G. Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters. J Infect Dis 1993, 167:920-924.
54. Walder B., Pittet D., Tramer M.R. Prevention of bloodstream infection depends on catheter type and insert time: evidence from a meta analysis. Infect Control Hosp Epidemiol 2002, 23:748-756.
55. Hu K.K., Veenstra D.L., Lipsky B.A., Saint S. Use of maximal sterile barriers during central venous catheter insertion: clinical and economic outcomes. Clin Infect Dis 2004, 39:1441-1445.
56. Crawford A.G., Fuhr J.P., Rao B. Cost-benefit analysis of chlorhexidine gluconate dressing in the prevention of catheter-related bloodstream infections. Infect Control Hosp Epidemiol 2004, 25:668-674.
57. Greco R.S., Harvey R.A. The role of antibiotic bonding in the prevention of vascular prosthetic infections. Ann Surg 1982, 195(2):168-171.
58. Hanna H., Benjamin R., Chatzinikolaou I., Alakech B., Richardson D., Mansfield P., Munsell M.F., Darouiche R., Kantarjian H., Raad I. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol 2004, 22(15):3163-3171.
59. Zhang X. Anti-infective coatings reduce device-related infections. Antimicrob? Anti-infection Mater 2000, 149-180.
60. Levy S.B. Antibiotic resistance - the problem intensifies. Adv Drug Delivery Rev 2005, 57(10):1446-1450.
61. Griintzig A. Transluminal dilation of coronary-artery stenosis. The Lancet 1978, 311(8058):263.
62. Heard S.O., Wagle M., Vijayakumar E., Mclean S., Brueggemann A., Napolitano L.M., Edwards L.P., O'Connell F.M., Puyana J.C., Doern G.V. Influence of triple-lumen central venous catheters coated With chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Intern Med 1998, 158:81-87.
63. Schierholz F.C., Beuth J., Pulverer G. The antimicrobial efficacy of a new central venous catheter with long-term broad-spectrum activity. J Antimicrobial Chemother 2000, 46:45-50.
64. Chaplin M.F. What are biosensors?. Molecular Biology and Biotechnology 2000, 521-545. Royal Society of Chemistry, Abington Hall, Cambridge, UK. J.M. Walker, R. Rapley (Eds.).
65. Ramanathan K., Danielsson B. Principles and applications of thermal biosensors. Biosensors and Bioelectronics 2001, 16(6):417-423.
66. Wang J. Electrochemical biosensors: towards point-of-care cancer diagnostics. Biosensors and Bioelectronics 2006, 21(10):1887-1892.
67. Fang Y. Non-invasive optical biosensor for probing cell signaling. Sensors 2007, 7:2316-2329.
68. Pohanka M., Treml F., Hubalek M., Baniouchova H., Beklova M., Pikula J. Piezoelectric biosensor for a simple serological diagnosis of tularemia in infected European brown hares (Lepus europaeus). Sensors 2007, 7:2825-2834.
69. Anderson J.M. Biological responses to materials. Annu Rev Mater Res 2001, 31:81-110.
70. Fournier P.C., Montero-Menei C.N., Benoit J.P. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003, 24(19):3311-3331.
71. Anderson J.M. Inflammatory response to implants. AOAIO Trans 1988, 34(2):101-107.
72. Jutila M.A. Leukocyte traffic to sites of inflammation. APMIS 1992, 100(3):191-201.
73. Anderson J.M., Rodriguez A., Chang D.T. Foreign body reaction to biomaterials. Semin Immunol 2008, 20(2):86-100.
74. Young Min Ju B.Y., Koob T.J., Moussy Y., Moussy F. A novel porous collagen scaffold around an implantable biosensor for improving biocompatibility. I. In vitro/in vivo stability of the scaffold and in vitro sensitivity of the glucose sensor with scaffold. J Biomed Mater Res Part B: Appl Biomater 2007, 87A(1):136-146.
75. Shen M., Horbett T.A. The effects of surface chemistry and adsorbed proteins on monocyte/macrophage adhesion to chemically modified polystyrene surfaces. J Biomed Mater Res 2001, 57(3):336-345.
76. Tsai W.B., Grunkemeier J.M., Mcfarland C.D., Horbett T.A. Platelet adhesion to polystyrene-based surfaces preadsorbed with plasmas selectively depleted in fibrinogen, fibronectin, vitronectin, or von Willebrand's factor. J Biomed Mater Res 2002, 60(3):348-359.
77. Dalsin J.L., Hu B.H., Lee B.P., Messersmith P.B. Mussel adhesive protein mimetic polymers for the preparation of nonfouling surfaces. J Am Chem Soc 2003, 125(14):4253-4258.
78. Paradossi G., Cavalieri F., Chiessi E., Spagnoli C., Cowman M.K. Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications. J Mater Sci Mater Med 2003, 14(8):687-691.
79. Maruoka S., Matsuura T., Kawasaki K., Okamoto M., Yoshiaki H., Kodama M., Sugiyama M., Annaka M. Biocompatibility of polyvinylalcohol gel as a vitreous substitute. Curr Eye Res 2006, 31(7-8):599-606.
80. Oka M., Ushio K., Kumar P., Ikeuchi K., Hyon S.H., Nakamura T., Fujita H. Development of artificial articular cartilage. Proc Inst Mech Eng [H] 2000, 214(1):59-68.
81. Royals M.A., Fujita S.M., Yewey G.L., Rodriguez J., Schultheiss P.C., Dunn R.L. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res 1999, 45(3):231-239.
82. Ronneberger B., Kissel T., Anderson J.M. Biocompatibility of ABA triblock copolymer microparticles consisting of poly(L-lactic-co-glycolic-acid) A-blocks attached to central poly(oxyethylene) B-blocks in rats after intramuscular injection. Eur J Pharm Biopharm 1997, 43:19-28.
83. Lunsford L., Mckeever U., Eckstein V., Hedley M.L. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. J Drug Target 2000, 8(1):39-50.
84. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Delivery Rev 1997, 28(1):5-24.
85. Athanasiou K.A., Niederauer G.G., Agrawal C.M. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996, 17(2):93-102.
86. Daugherty A.L., Cleland J.L., Duenas E.M., Mrsny R.J. Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres. Eur J Pharm Biopharm 1997, 44(1):89-102.
87. Patil S., Papadimitrakopoulos F., Burgess D.J. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Controlled Rel 2007, 117(1):68-79.
88. Patil S.D., Papadimitrakopoulos F., Burgess D.J. Dexamethasone-loaded poly(lactic-co-glycolic) acid microspheres/poly(vinyl alcohol) hydrogel composite coatings for inflammation control. Diabetes Technol Therapeutics 2004, 6(6):887-897.
89. Galeska I., Kim T.-K., Patil S.D., Bhardwaj U., Chatttopadhyay D., Papadimitrakopoulos F., Burgess D.J. Controlled release of dexamethasone from PLGA microspheres embedded within polyacid-containing PVA hydrogels. AAPSJ 2005, 7(1):231-240.
90. Bhardwaj U., Sura R., Papadimitrakopoulos F., Burgess D.J. Controlling acute inflammation with fast releasing dexamethasone-PLGA microsphere/PVA hydrogel composites for implantable devices. J Diabetes Sci Technol 2007, 1(1):8-17.
91. Norton L.W., Koschwanez H.E., Wisniewski N.A., Klitzman B., Reichert W.M. Vascular endothelial growth factor and dexamethasone release from nonfouling sensor coatings affect the foreign body response. J Biomed Mater Res Part B: Appl Biomater 2007, 81B(4):858-869.
92. Jaeyun S., Barone P.W., Kong Hyunjoon S.M.S. Sequential delivery of dexamethasone and VEGF to control local tissue response for carbon nanotube fluorescence based micro-capillary implantable sensors. Biomaterials 2009, 30(4):622-631.
93. Long P.H. Medical devices in orthopedic applications. Toxicologic Pathol 2008, 36(1):85-91.
94. Garvin K.L., Hansen A.D. Infection after total hip arthroplasty. Past, present, and future. J Bone Joint Surg Am 1995, 77:1576-1588.
95. Masri B.A., Duncan C.P., Beauchamp C.P. Long-term elution of antibiotics from bone-cement: an in vivo study using the prosthesis of antibiotic-loaded acrylic cement (PROSTALAC) system. J Arthroplasty 1998, 13:331-338.
96. Buchholz H.W., Engelbrecht H. Depot effects of various antibiotics mixed with Palacos resins. Der Chirurg 1970, 41:511-515.
97. Trippel S.B. Antibiotic-impregnated cement in total joint arthroplasty. J Bone Joint Surg Am 1986, 68(8):1297-1302.
98. Faber C., Stallmann H., Lyaruu D.M., De Blieck J.M.A., Bervoets T.J.M., Van Nieuw Amerongen A. Release of antimicrobial peptide Dhvar-5 from polymethyl methacrylate beads. J Antimicrob Chemother 2003, 51(6):1358-1364.
99. Koller G., Bruce R.J., Deb S.K. Antimicrobial potential of bioactive bone cements. J Appl Biomater Biomechanics 2008, 6(1):16-22.
100. Boger A., Bohner M., Heini P., Verrier S., Schneider E. Properties of an injectable low modulus PMMA bone cement for osteoporotic bone. J Biomed Mater Res, Part B: Appl Biomater 2008, 86B(2):474-482.
101. Tuzuner T., Sencan I., Ozdemir D., Alper M., Duman S., Yavuz T., Yildirim M. In vivo evaluation of teicoplanin- and calcium sulfate-loaded PMMA bone cement in preventing implant-related osteomyelitis in rats. J Chemotherapy (Firenze, Italy) 2006, 18(6):628-633.
102. Sterling G.J., Crawford S., Potter J.H., Koerbin G., Crawford R. The pharmacokinetics of Simplex-tobramycin bone cement. J Bone Joint Surg Br 2003, 85(5):646-649.
103. Neut D., Van De Belt H., Stokroos I., Van Horn J.R., Van Der Mei H.C., Busscher H.J. Biomaterial-associated infection of gentamicin-loaded PMMA beads in orthopedic revision surgery. J Antimicrob Chemother 2001, 47(6):885-891.
104. Frutos Cabanillas P., Diez Pena E., Barrales-Rienda J.M., Frutos G. Validation and in vitro characterization of antibiotic-loaded bone cement release. Int J Pharmaceutics 2000, 209(1-2):15-26.
105. Burg K.J.L., Porter S., Kellam J.F. Biomaterial developments for bone tissue engineering. Biomaterials 2000, 21(23):2347-2359.
106. Middleton J.C., Tipton A.J. Synthetic biodegradable polymers as orthopedic devices. Biomaterials 2000, 21(23):2335-2346.
107. Hanssen A.D., Rand J.A., Osmon D.R. Treatment of the infected total knee arthroplasty with insertion of another prosthesis. The effect of antibiotic-impregnated bone cement. Clin Orthop 1994, 309:44-55.
108. Jackson W.O., Schmalzried T.P. Limited role of direct exchange arthroplasty in the treatment of infected total hip replacements. Clin Orthop 2000, 381:101-105.
109. Raut V.V., Siney P.D., Wroblewski B.M. One-stage revision of total hip arthroplasty for deep infection. Long-term followup. Clin Orthop 1995, 321:202-207.
110. Wentworth S.J., Masri B.A., Duncan C.P., Southworth C.B. Hip prosthesis of antibiotic-loaded acrylic cement for the treatment of infections following total hip arthroplasty. J Bone Joint Surg Am 2002, 84:123-128.
111. Younger A.S., Duncan C.P., Masri B.A., Mcgraw R.W. The outcome of two-stage arthroplasty using a custom-made interval spacer to treat the infected hip. J Arthroplasty 1997, 12:615-623.
112. Perez-Sayans M., et al. Peri-implant bone resorption around implants placed in alveolar bone subjected to distraction osteogenesis. J Oral Maxillofacial Surgery 2008, 66(4):787-790.
113. Stadelamann V.A., Terrier A., Pioletti D.P. Osteoclastogenesis can be mechanically-induced in the peri-implant bone. IRBM 2009, 30(1):10-13.
114. Shanbhag A.S. Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg 2006, 14(4):215-225.
115. Von Knoch F., et al. Anabolic effects of bisphosphonates on peri-implant bone stock. Biomaterials 2007, 28(24):3549-3559.
116. Lehmann H.J., Mouritzen U., Christgau S., Cloos P.A., Christiansen C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 2002, 61(6):530-533.
117. Maksymowych W.P. Bisphosphonates for arthritis - a confusing rationale. J Rheumatol 2003, 30(3):430-434.
118. Von Knoch F., Jaqulery C., Kowalsky M., Schaeren S.C. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005, 26(34):6941-6949.
119. Segal M. Patches, pumps and timed release: new ways to deliver drugs, Food and Drug Administration 2007, Editor. http://www.fda.gov/bbs/topics/consumer/CON00112.html.
120. Parrott A.C., Jones R. Effects of transdermal scopolamine upon psychological test performance at sea. Eur J Clin Pharmacol 1985, 28(4):419-423.
121. Hall K.A., Keks N.A., O'Connor D. Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial. Int Psychogeriatrics 2005, 17(2):165-178.
122. Han C., Jung P., Sanders S.W., Lin E.T., Benet L.Z. Pharmacokinetics of nitroglycerin and its four metabolites during nitroglycerin transdermal administration. Biopharmaceutics & Drug Disposition 2006, 15(2):179-183.
123. Galer B.S. Clinical significance of transdermal lidocaine patch. Drug Deliv Syst 2003, 18(3):228.
124. Kuldeep G., Avinash K., Pathak A.K. Formulation and evaluation of transdermal patch of Colchicine with release modifiers. Pharmacist (Bhopal, India) 2007, 2(2):21-23.
125. Wang Q., Weiwu C., Hailong L. Transdermal patch of Aconitum sinomontanum, its formulation and application as anti-inflammatory and antalgic agents. Faming Zhuanli Shenqing Gongkai Shuomingshu 2009.
126. Hair P.I., Keating G.M., Mckeage K. Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain. Drugs 2008, 68(14):2001-2009.
127. Kilic N., Emin B., Semra A., Nuri S., Hassan D. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Int J Urology 2006, 13(2):105-108.
128. Wagg A. Transdermal oxybutynin: topical therapy for overactive bladder syndrome. Expert Rev Obstetrics Gynecol 2008, 3(2):175-179.
129. Kumar R., Philip A. Modified transdermal technologies: breaking the barriers of drug permeation via the skin. Tropical J Pharmaceutical Res 2007, 6(1):633-644.
130. Shah S. Transdermal drug delivery technology revisited: recent advances. Pharmaceut Rev 2008, 6(5). (available online).
131. Talton J.D. Compositions for delivery of poorly soluble drugs. US Pat. Appl. Publ 2009.
132. Siegel S.J., O'Neill C., Dube L.M., Kaldeway P., Morris R., Jackson D., Sebree T. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharmaceut Res 2007, 24(10):1919-1926.
133. Li F., Bao-Hua H., Li W.-Z., Liu S., Tang B.-B., Du S.-J. Pharmacokinetics of transdermal absorption of Sinomenine in patch under electroporation condition. Dier Junyi Daxue Xuebao 2008, 29(9):1096-1098.
134. Kuwahara T., Seiji T., Matsudo T. Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing the same. PCT Int. Appl. 2008.
135. Teo A.L., et al. Transdermal microneedles for drug delivery applications. Mater Sci Eng: B 2006, 132(1-2):151-154.
136. Gill H.S., Prausnitz M.R. Coated microneedles for transdermal delivery. J Control Rel 2007, 117(2):227-237.
137. Prausnitz M.R., Langer R. Transdermal drug delivery. Nature Biotechnol 2008, 26:1261-1268.
138. Menon G.K., Nikiforos K., Doukas A.G. Ultrastructural evidence of stratum corneum permeabilization induced by photomechanical waves. J Investigative Dermatol 2003, 121(1):104-109.
139. Lee S., Mcauliffe D.J., Kollias N., Flotte T.J., Doukas A.G. Permeabilization and recovery of the stratum corneum in vivo: the synergy of photomechanical waves and sodium lauryl sulfate. Lasers Surgery Med 2001, 29(2):145-150.